Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics

• Main Authors: Ananya Pal, Hsin Yao Chiu, Reshma Taneja
• Format: Article
• Language: English
• Published: Elsevier 2019-07-01
• Series: Redox Biology
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213231718311406

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma accounting for 5–8% of malignant tumours in children and adolescents. Children with high risk disease have poor prognosis. Anti-RMS therapies include surgery, radiation and combination chemotherapy. While these strategies improved survival rates, they have plateaued since 1990s as drugs that target differentiation and self-renewal of tumours cells have not been identified. Moreover, prevailing treatments are aggressive with drug resistance and metastasis causing failure of several treatment regimes. Significant advances have been made recently in understanding the genetic and epigenetic landscape in RMS. These studies have identified novel diagnostic and prognostic markers and opened new avenues for treatment. An important target identified in high throughput drug screening studies is reactive oxygen species (ROS). Indeed, many drugs in clinical trials for RMS impact tumour progression through ROS. In light of such emerging evidence, we discuss recent findings highlighting key pathways, epigenetic alterations and their impacts on ROS that form the basis of developing novel molecularly targeted therapies in RMS. Such targeted therapies in combination with conventional therapy could reduce adverse side effects in young survivors and lead to a decline in long-term morbidity. Keywords: Rhabdomyosarcoma, Transcription, Signalling, Redox homeostasis, Therapeutics